Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

47
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
47
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

252
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
252
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

182
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
182
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

202
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
202
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

410
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
410
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

524
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
524

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The renin angiotensin system in cognitive flexibility: Effects of single-dose losartan on task-switching in healthy volunteers.

Journal of psychopharmacology (Oxford, England)·2026
Same author

The cognitive neuroscience of ketamine in major depression.

Brain : a journal of neurology·2025
Same author

Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label Trial.

The Journal of clinical psychiatry·2025
Same author

Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia.

Molecular psychiatry·2025
Same author

Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial.

Biological psychiatry·2025
Same author

Acute angiotensin receptor blockade and mnemonic discrimination in healthy participants.

Journal of affective disorders·2025

Related Experiment Video

Updated: Jul 11, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.3K

Ketamine for Major Depressive Disorder.

Sara Costi1,2,3

  • 1Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. sara.costi@psych.ox.ac.uk.

Current Topics in Behavioral Neurosciences
|November 3, 2023
PubMed
Summary
This summary is machine-generated.

Ketamine, an NMDA receptor antagonist, offers rapid and sustained antidepressant effects for Major Depressive Disorder (MDD). It provides a novel treatment option for treatment-resistant depression, improving upon conventional therapies.

Keywords:
EsketamineGlutamateKetamineMajor depressive disorderSuicideTreatment resistant depression

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K

Related Experiment Videos

Last Updated: Jul 11, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.3K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.9K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.6K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Major Depressive Disorder (MDD) is a global health concern, causing significant disability.
  • Current antidepressants have slow onset (2 weeks) and limited efficacy, failing one-third of patients.
  • Treatment-resistant depression (TRD) requires novel therapeutic strategies.

Purpose of the Study:

  • To review the pharmacology, safety, and efficacy of ketamine for MDD.
  • To evaluate ketamine's potential as a rapid-acting antidepressant for TRD.
  • To explore ketamine's impact on suicidal ideation and treatment response biomarkers.

Main Methods:

  • Review of existing literature on ketamine's antidepressant properties.
  • Analysis of pharmacological mechanisms, including NMDA receptor antagonism.
  • Examination of clinical trial data regarding efficacy, safety, and duration of effect.

Main Results:

  • Ketamine demonstrates rapid antidepressant effects within hours, lasting up to 7 days.
  • It shows significant efficacy in patients with treatment-resistant depression.
  • Ketamine influences suicidal ideation and has associated brain biomarkers for treatment response.

Conclusions:

  • Ketamine represents a paradigm shift in MDD treatment, offering rapid and sustained symptom relief.
  • Its efficacy in TRD warrants further investigation and clinical application.
  • The combination of ketamine with psychotherapy may enhance treatment outcomes.